Imugene和JW治疗 正在测试一种新的癌症治疗 结合病毒和CAR-T治疗 以固态肿瘤为目标。 Imugene and JW Therapeutics are testing a new cancer treatment that combines a virus and CAR-T therapy to target solid tumors.

Imugene 和 JW 治疗学合作, 测试新颖的“标记和杀死”癌症疗法, 将Imugene的肿瘤病毒CF33-CD19与JW的CD19(针对CAR-T)疗法卡泰瓦(Carteyva)相结合, 用于治疗先进的固态肿瘤。 Imugene and JW Therapeutics have launched a collaboration to test a novel "mark and kill" cancer therapy combining Imugene’s oncolytic virus CF33-CD19 with JW’s CD19-targeted CAR-T therapy Carteyva for advanced solid tumors. 该方法利用病毒使肿瘤细胞表现CD19,使CAR-T细胞能够瞄准它们。 The approach uses the virus to make tumor cells express CD19, enabling CAR-T cells to target them. 中国的临床预科研究和第一阶段试验将评价这种结合,旨在将CAR-T治疗扩大到血液癌之外。 Preclinical studies and a Phase 1 trial in China will evaluate the combination, aiming to expand CAR-T treatment beyond blood cancers. 这种合作关系利用JW的制造和临床基础设施,生成支持未来发展的数据,并确定了指导进展的里程碑. The partnership leverages JW’s manufacturing and clinical infrastructure to generate data supporting future development, with defined milestones to guide progress.